Q3 2024 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2024-11-14 · accession 0001839435-24-000008
$642.9M
Reported value
42
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $86.7M | 13.5% | 3,006,980 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $52.8M | 8.21% | 1,835,200 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $52.6M | 8.18% | 1,198,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $47.8M | 7.44% | 1,746,667 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $46.4M | 7.22% | 1,976,387 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $32.2M | 5.00% | 2,012,052 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $31.9M | 4.96% | 436,820 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $27.9M | 4.34% | 12,171,513 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $23.0M | 3.58% | 1,115,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $21.1M | 3.28% | 2,425,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $19.8M | 3.08% | 870,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $19.0M | 2.95% | 1,422,224 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $18.3M | 2.84% | 250,000 | CALL | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $17.2M | 2.67% | 3,018,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $14.1M | 2.19% | 1,305,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $14.1M | 2.19% | 552,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $11.5M | 1.79% | 620,470 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $9.4M | 1.47% | 262,726 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $9.2M | 1.43% | 4,572,222 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $9.1M | 1.41% | 9,187,883 | Common | SOLE |
| 019818103 | — | ALLOVIR INC | $9.1M | 1.41% | 11,202,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $8.7M | 1.36% | 1,093,503 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $7.5M | 1.16% | 130,000 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $7.3M | 1.13% | 600,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $6.7M | 1.04% | 4,263,701 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $5.2M | 0.81% | 2,391,114 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $5.0M | 0.77% | 2,576,200 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $4.4M | 0.68% | 489,596 | Common | SOLE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $3.8M | 0.59% | 2,250,000 | Common | SOLE |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $3.5M | 0.54% | 8,559,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $3.2M | 0.50% | 376,117 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $2.6M | 0.41% | 250,000 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $2.6M | 0.40% | 594,000 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $2.4M | 0.37% | 400,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $1.9M | 0.29% | 992,000 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $1.1M | 0.18% | 666,825 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $972,770 | 0.15% | 465,440 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $715,249 | 0.11% | 312,336 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $638,880 | 0.10% | 176,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $629,400 | 0.10% | 15,000 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $586,920 | 0.09% | 292,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $542,400 | 0.08% | 120,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.